医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Sucampo and Takeda Enter into Global Licensing Agreement for AMITIZA® (lubiprostone)

2014年10月23日 PM05:23
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ:4573):

Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global license, development, commercialization and supply agreement for AMITIZA® (lubiprostone). (See Sucampo press release)

Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA® in all global markets, except Japan and the People’s Republic of China.

R-Tech Ueno has a global exclusive manufacturing and supply right to AMITIZA®.

As a result of the above, there are no changes to the business forecasts throughout the year that were published on May 14, 2014.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/141023_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials
  • 2023年扎耶德可持续发展奖持续彰显全球影响力,收获超4,500份申请
  • ザーイド・サステナビリティ賞2023年度の応募を締切り、最終応募数は4,500件超に!
  • U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia
  • Avivagen Announces Receipt of Repeat Order from Asian Customer